Item 8.01 Other Events.

On February 6, 2023, PDS Biotechnology Corporation issued a press release announcing an abstract investigating the ability of PDS0101 in combination with KEYTRUDA® (pembrolizumab) to induce HPV16-specific CD4 and CD8 T cell activation and functionality has been accepted for presentation at the ESMO Targeted Anticancer Therapies Congress 2023 (ESMO TAT) in Paris, March 6-8 2023.

A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.

Exhibit
 Number                                    Description

  99.1     Press Release Dated February 6, 2023.
  104      Cover Page Interactive Data File (embedded within the Inline XBRL Document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses